Curium to acquire Lantheus for up to $114.50/share, ~$8B, largest radiopharma deal ever
Plus: American Oncology Network now runs 9 radioligand therapy centers, up from 1 in 2023. The day's rules, money, and enforcement, sourced and tiered below.
Plus: American Oncology Network now runs 9 radioligand therapy centers, up from 1 in 2023. The day's rules, money, and enforcement, sourced and tiered below.
|
American Health Intel
Rules · Money · Medicine · Decoded daily
|
| The Service Line |
Wednesday, August 5, 2026 |
|
|
Curium to acquire Lantheus for up to $114.50/share, ~$8B, largest radiopharma deal ever
|
|
Plus: American Oncology Network now runs 9 radioligand therapy centers, up from 1 in 2023. The day's rules, money, and enforcement, sourced and tiered below.
|
|
|
Record
Curium, a manufacturer of the radioactive drugs used to find and treat cancer, agreed to buy Lantheus, maker of the leading prostate cancer PET scan, for up to 114.50 dollars a share, about 8 billion dollars total.
Announced August 3, 2026, the largest deal in radiopharmaceutical industry history. Lantheus's PYLARIFY scan alone made 240.9 million dollars in Q1 2026. Deal expected to close first half of 2027.
|
|
Record
American Oncology Network, a network of community cancer practices, said it now operates 9 centers offering radioligand therapy, a targeted radiation cancer treatment, up from just 1 center in 2023.
Announced July 23, 2026, with 5 more centers in development and two new physician leaders overseeing radiology and radiation oncology. Shows delivery capacity concentrating alongside manufacturing.
|
|
Also today
CMS CY2027 physician fee schedule proposes 340B repository reporting and doubled ACO E/M bonus Read
GSK wins first lung cancer approval with zidesamtinib for ROS1-positive NSCLC Read
|
374 Records | $31.6B Enforcement | 17 Deadlines | 110 Rules |
|
|
Pick your field on the site and every story tells you what it means for you.
|
|
Reply to this email and tell us what you want covered. We read everything.
|
|
We show our work. We score our own calls.
News and analysis, not legal, medical, coding, or investment advice.
You subscribed at americanhealthintel.com · Unsubscribe
|
|